CM
MRTX

Crestline Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Crestline Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-26,212
Closed -$805K – 296
2018
Q1 		$805K Buy
+26,212
New +$728K 0.1% 166

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Crestline Management's MRTX Position: Q2 2018 in Review

Crestline Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2018, closing a stake of 26,212 shares — an estimated $805K sold.

Crestline Management first reported a position in MRTX in Q1 2018 and held it in 1 quarter. The position peaked at $805K in Q1 2018. 108 funds tracked by Wall St. Rank hold MRTX as of Q2 2018.

  • Crestline Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Crestline Management sold 26,212 Mirati Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $805K.
  • Crestline Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Crestline Management's Mirati Therapeutics, Inc. Common Stock position peaked at $805K in Q1 2018.
  • 108 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Crestline Management's 13F filing for Q2 2018, filed 14 Aug 2018.